OpenLB
Open Library of Bioscience
Advanced Search
Molecules (Basel, Switzerland)
Nov 14, 2017;22 (11):

Design, Recombinant Fusion Expression and Biological Evaluation of Vasoactive Intestinal Peptide Analogue as Novel Antimicrobial Agent.

Chunlan Xu, Yu Guo, Xiangjin Qiao, Xiaoya Shang, Weining Niu, Mingliang Jin
Author Information
  1. Chunlan Xu: The Key Laboratory for Space Bioscience and Biotechnology, School of Life Sciences, Northwestern Polytechnical University, Xi'an 710072, China. clxu@nwpu.edu.cn.
  2. Yu Guo: The Key Laboratory for Space Bioscience and Biotechnology, School of Life Sciences, Northwestern Polytechnical University, Xi'an 710072, China. gydebbie@hotmail.com.
  3. Xiangjin Qiao: The Key Laboratory for Space Bioscience and Biotechnology, School of Life Sciences, Northwestern Polytechnical University, Xi'an 710072, China. qiaoxj2009@163.com.
  4. Xiaoya Shang: The Key Laboratory for Space Bioscience and Biotechnology, School of Life Sciences, Northwestern Polytechnical University, Xi'an 710072, China. loyamuyu@nwpu.edu.cn.
  5. Weining Niu: The Key Laboratory for Space Bioscience and Biotechnology, School of Life Sciences, Northwestern Polytechnical University, Xi'an 710072, China. niuweining@nwpu.edu.cn.
  6. Mingliang Jin: The Key Laboratory for Space Bioscience and Biotechnology, School of Life Sciences, Northwestern Polytechnical University, Xi'an 710072, China. mljin@nwpu.edu.cn.
PMID: 29135962 DOI: 10.3390/molecules22111963

Abstract

Antimicrobial peptides represent an emerging category of therapeutic agents with remarkable structural and functional diversity. Modified vasoactive intestinal peptide (VIP) (VIP analogue 8 with amino acid sequence "FTANYTRLRRQLAVRRYLAAILGRR") without haemolytic activity and cytotoxicity displayed enhanced antimicrobial activities against () ATCC 25923 and () ATCC 25922 than parent VIP even in the presence of 180 mM NaCl or 50 mM MgCl₂, or in the range of pH 4-10. VIP analogue 8 was expressed as fusion protein thioredoxin (Trx)-VIP8 in BL21(DE) at a yield of 45.67 mg/L. The minimum inhibitory concentration (MIC) of the recombinant VIP analogue 8 against ATCC 25923 and ATCC 25922 were 2 μM. These findings suggest that VIP analogue 8 is a promising candidate for application as a new and safe antimicrobial agent.

Keywords

Escherichia coli analogue antimicrobial activity recombinant expression vasoactive intestinal peptide

References

  1. J Immunol. 2012 Jul 1;189(1):269-78 [PMID: 22661083]
  2. Biochim Biophys Acta. 1997 Jul 5;1327(1):119-30 [PMID: 9247173]
  3. J Biol Chem. 1999 May 7;274(19):13181-92 [PMID: 10224074]
  4. Eur J Pharmacol. 2004 Feb 6;485(1-3):307-16 [PMID: 14757155]
  5. Plant Biotechnol J. 2011 Jan;9(1):100-15 [PMID: 20553419]
  6. Saudi Pharm J. 2016 Sep;24(5):515-524 [PMID: 27752223]
  7. Front Cell Infect Microbiol. 2016 Dec 27;6:194 [PMID: 28083516]
  8. PLoS One. 2015 Mar 18;10(3):e0119525 [PMID: 25785690]
  9. Proc Jpn Acad Ser B Phys Biol Sci. 2012;88(4):152-66 [PMID: 22498979]
  10. Pharmaceuticals (Basel). 2013 Aug 21;6(8):1055-81 [PMID: 24276381]
  11. J Agric Food Chem. 2013 Apr 24;61(16):3901-8 [PMID: 23590460]
  12. Curr Protein Pept Sci. 2012 Dec;13(8):723-38 [PMID: 23305360]
  13. J Neuroimmunol. 2011 Apr;233(1-2):37-45 [PMID: 21176972]
  14. J Biol Chem. 2014 May 23;289(21):14583-99 [PMID: 24706753]
  15. Lancet Infect Dis. 2016 Feb;16(2):239-51 [PMID: 26795692]
  16. Methods Mol Biol. 2010;618:61-76 [PMID: 20094858]
  17. Peptides. 2017 Nov;97:46-53 [PMID: 28962891]
  18. J Microbiol. 2017 Jan;55(1):1-12 [PMID: 28035594]
  19. Methods Mol Biol. 2011;681:259-80 [PMID: 20978970]
  20. Appl Microbiol Biotechnol. 2013 Apr;97(8):3535-43 [PMID: 23053091]
  21. J Neuroimmunol. 2008 Aug 30;200(1-2):11-6 [PMID: 18603306]
  22. Biopolymers. 2006 Feb 5;81(2):110-9 [PMID: 16224772]
  23. Appl Microbiol Biotechnol. 2014 Apr;98(8):3651-58 [PMID: 24121930]
  24. Saudi Pharm J. 2017 Jan;25(1):25-31 [PMID: 28223859]
  25. Protein Pept Lett. 2013 Jan;20(1):54-60 [PMID: 22670762]
  26. Curr Pharm Des. 2010;16(9):1063-80 [PMID: 20030612]
  27. Nat Biotechnol. 2006 Dec;24(12):1551-7 [PMID: 17160061]
  28. Appl Microbiol Biotechnol. 2009 Aug;84(2):301-8 [PMID: 19373462]
  29. Biochem Biophys Res Commun. 1985 May 16;128(3):1093-8 [PMID: 4004849]
  30. Biotechnology (N Y). 1993 Feb;11(2):187-93 [PMID: 7763371]
  31. Pharmacol Rev. 2003 Mar;55(1):27-55 [PMID: 12615953]
  32. Cell. 1997 Feb 21;88(4):553-60 [PMID: 9038346]

MeSH Term

Amino Acid Sequence
Animals
Anti-Bacterial Agents
Anti-Infective Agents
Drug Design
Hemolysis
Mice
Microbial Sensitivity Tests
Recombinant Fusion Proteins
Vasoactive Intestinal Peptide

Chemicals

Anti-Bacterial Agents
Anti-Infective Agents
Recombinant Fusion Proteins
Vasoactive Intestinal Peptide
Journal Article

Word Cloud

Created with Highcharts 10.0.0VIPanalogue8ATCCantimicrobialAntimicrobialvasoactiveintestinalpeptideactivity2592325922mMrecombinantpeptidesrepresentemergingcategorytherapeuticagentsremarkablestructuralfunctionaldiversityModifiedaminoacidsequence"FTANYTRLRRQLAVRRYLAAILGRR"withouthaemolyticcytotoxicitydisplayedenhancedactivitiesparentevenpresence180NaCl50MgCl₂rangepH4-10expressedfusionproteinthioredoxinTrx-VIP8BL21DEyield4567mg/LminimuminhibitoryconcentrationMIC2μMfindingssuggestpromisingcandidateapplicationnewsafeagentDesignRecombinantFusionExpressionBiologicalEvaluationVasoactiveIntestinalPeptideAnalogueNovelAgentEscherichiacoliexpression

Similar Articles

Cited By